Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Louisiana Purchase: State Eager To Test “Netflix Model” For Rx Spending

Executive Summary

A subscription payment model could be a solution for high-priced drugs, Louisiana thinks – and appears to have at least one manufacturer willing to participate. Will the Trump Administration agree?

You may also be interested in...



Louisiana ‘Netflix’ Model For Hepatitis C Drugs Caps Spending At $35m Per Year

Purchasing contract for state Medicaid and Corrections programs would last up to five years and aim to treat more than 10,000 patients in first year.

Pivot To Video? “Netflix” Rx Pricing Model Plays Well With Media

A subscription model for drug pricing isn’t an entirely new idea, but it is a timely one. If nothing else, the idea of a “Netflix” approach appeals to media savvy audiences. 

Gilead’s Price Reduction Strategy: A Serious Move, But Not A Long-Term Model For US

“Authorized generics” for Gilead's leading hepatitis C brands stands out from prior, largely symbolic responses to the lower list prices. This is not a political move, but a business one. It is also the clearest demonstration yet of why pricing reforms are necessary if lower list prices are the policy goal.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel